Safety and Immunogenicity of Adenovirus and Poxvirus Vectored Vaccines against a Mycobacterium Avium Complex Subspecies

Heterologous prime-boost strategies are known to substantially increase immune responses in viral vectored vaccines. Here we report on safety and immunogenicity of the poxvirus Modified Vaccinia Ankara (MVA) vectored vaccine expressing four Mycobacterium avium subspecies paratuberculosis antigens as...

Descripción completa

Detalles Bibliográficos
Autores principales: Folegatti, Pedro M., Flaxman, Amy, Jenkin, Daniel, Makinson, Rebecca, Kingham-Page, Lucy, Bellamy, Duncan, Ramos Lopez, Fernando, Sheridan, Jonathan, Poulton, Ian, Aboagye, Jeremy, Tran, Nguyen, Mitton, Celia, Roberts, Rachel, Lawrie, Alison M., Hill, Adrian V. S., Ewer, Katie J., Gilbert, Sarah
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8000717/
https://www.ncbi.nlm.nih.gov/pubmed/33809415
http://dx.doi.org/10.3390/vaccines9030262
Descripción
Sumario:Heterologous prime-boost strategies are known to substantially increase immune responses in viral vectored vaccines. Here we report on safety and immunogenicity of the poxvirus Modified Vaccinia Ankara (MVA) vectored vaccine expressing four Mycobacterium avium subspecies paratuberculosis antigens as a single dose or as a booster vaccine following a simian adenovirus (ChAdOx2) prime. We demonstrate that a heterologous prime-boost schedule is well tolerated and induced T-cell immune responses.

Ejemplares similares